US5185376A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic inhibition of platelet aggregation by nucleophile-nitric oxide complexes and derivatives thereof
Assignee: United States Department of Health and Human Services
•
Filing: 1991-09-24
•
Granted: 1993-02-09
•
Expires: 2011-09-24
Abstract
Abstract A method of inhibiting platelet aggregation in vivo with physiologically compatible compounds containing at least one N-oxo-N-nitrosoamine moiety in a molecule thereof, wherein the physiologically compatible compound releases nitric oxide in a sustained and controllable fashion in vivo.
Inventors
- 👤 Jean G. Diodati
- 👤 Larry K. Keefer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 05:44
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61P; A61P7/00; A61P7/02
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
58 words
A method of inhibiting platelet aggregation in vivo, in a patient in need thereof, the method comprising: administering to the patient an effective platelet aggregation inhibiting amount of a physiologically compatible compound containing at least one N-oxo-N-nitrosoamine moiety in a molecule thereof, wherein the physiologically compatible compound releases nitric oxide in vivo in a controllable and sustained fashion.
Claim 2
Independent Claim
58 words
A method of inhibiting platelet aggregation in vivo, in a patient in need thereof, the method comprising: administering to the patient an effective platelet aggregation inhibiting amount of a physiologically compatible compound containing at least one N-oxo-N-nitrosoamine moiety in a molecule thereof, wherein the physiologically compatible compound releases nitric oxide in vivo in a controllable and sustained fashion.
Claim 3
Dependent Claim
18 words
The method of claim 1, wherein said physiologically compatible compound is administered to the patient by intravenous injection.
Claim 4
Dependent Claim
20 words
The method of claim 2, wherein said physiologically compatible compound is administered in an amount of 0.01 to 10.0 mg/kg/day.
Claim 5
Independent Claim
57 words
A method of inhibiting platelet aggregation in vivo, in a patient in need thereof, the method comprising: administering to the patient an effective platelet aggregation inhibiting amount of a physiologically compatible compound which is (C 2 H 5 ) 2 --N--N(ONa)--N═O, wherein the physiologically compatible compound releases nitric oxide in vivo in a controllable and sustained fashion.
Claim 6
Independent Claim
57 words
A method of inhibiting platelet aggregation in vivo, in a patient in need thereof, the method comprising: administering to the patient an effective platelet aggregation inhibiting amount of a physiologically compatible compound which is (C 2 H 5 ) 2 --N--N(ONa)--N═O, wherein the physiologically compatible compound releases nitric oxide in vivo in a controllable and sustained fashion.
Claim 7
Dependent Claim
18 words
The method of claim 4, wherein said physiologically compatible compound is administered to the patient by intravenous injection.
Claim 8
Dependent Claim
20 words
The method of claim 5, wherein said physiologically compatible compound is administered in an amount of 0.01 to 10.0 mg/kgday.
Claim 9
Independent Claim
55 words
A method of inhibiting platelet aggregation in vivo, in a patient in need thereof, the method comprising: administering to the patient an effective platelet aggregation inhibiting amount of a physiologically compatible compound which is spermine bis (nitric oxide) adduct, wherein the physiologically compatible compound releases nitric oxide in vivo in a controllable and sustained fashion.
Claim 10
Independent Claim
55 words
A method of inhibiting platelet aggregation in vivo, in a patient in need thereof, the method comprising: administering to the patient an effective platelet aggregation inhibiting amount of a physiologically compatible compound which is spermine bis (nitric oxide) adduct, wherein the physiologically compatible compound releases nitric oxide in vivo in a controllable and sustained fashion.
Claim 11
Dependent Claim
18 words
The method of claim 7, wherein said physiologically compatible compound is administered to the patient by intravenous injection.
Claim 12
Dependent Claim
20 words
The method of claim 8, wherein said physiologically compatible compound is administered in an amount of 0.01 to 10.0 mg/kg/day.
References Cited (Backward Citations)
US4954526A
Cited
US5039705A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-02-09 | 1996-08-10 | 1997-02-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-02-09 | 2000-08-10 | 2001-02-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-02-09 | 2004-08-10 | 2005-02-09 | $7700.00 | Window Closed / Lapsed |